{"denoms":[{"counts":[{"groupId":"BG000","value":"911"},{"groupId":"BG001","value":"911"},{"groupId":"BG002","value":"1822"}],"units":"Participants"}],"groups":[{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Arm I (Zoledronic Acid Every 4 Weeks)"},{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Arm II (Zoledronic Acid Every 12 Weeks)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.1","value":"65.3"},{"groupId":"BG001","spread":"11.7","value":"65.3"},{"groupId":"BG002","spread":"11.9","value":"65.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"414"},{"groupId":"BG001","value":"428"},{"groupId":"BG002","value":"842"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"497"},{"groupId":"BG001","value":"483"},{"groupId":"BG002","value":"980"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"911"},{"groupId":"BG001","value":"911"},{"groupId":"BG002","value":"1822"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"All baseline patients demographics were analyzed."}